AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04932707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control (passive stretch exercises)
Description: The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
Study NCT05004272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: 20-minute manual full-body massage
Study NCT05004272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gymnastics
Description: 20-minute moderate body workout
Study NCT05004272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lecture
Description: 20-minute lecture on medicinal herbs
Study NCT05695833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Device emitting electric waves generating heat
Study NCT05695833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Device emitting electric waves generating heat
Study NCT05029115 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Dapagliflozin, Empagliflozin
Study NCT06346457 — intervention group
Intervention type: DRUG
Intervention: Tamoxifen
Description: Tamoxifen is 20 mg once daily for two to three weeks.
Study NCT06346457 — intervention group
Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole (Aromatase inhibitor) is 2,5 mg once daily for two to three weeks.
Study NCT06346457 — intervention group
Intervention type: DRUG
Intervention: Letrozole + GnRH
Description: When they take Letrozole + GnRh, the GnRh is an injection once a month.
Study NCT06260644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VertiseTM flowable composite (Kerr,USA)
Description: self adhesive flowable resin composite restoration.
Study NCT06260644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VertiseTM flowable composite (Kerr,USA)
Description: self adhesive flowable resin composite restoration.
Study NCT05856513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Participants receive ZSP1273 orally.
Study NCT06292494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate 4000 Transcranial MRgfUS System
Description: Focused ultrasound interrupt structure of epilepsy network to improve seizure.
Study NCT05045313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium tablets
Description: Drug: Warfarin sodium, tablet, oral
Study NCT05045313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: Drug: Digoxin, tablet, oral
Study NCT05045313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid tablets
Description: Drug: Probenecid, tablet, oral
Study NCT05045313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral
Study NCT04628572 — intervention group
Intervention type: DRUG
Intervention: Ceftazidime-avibactam
Description: Non-Interventional Study
Study NCT04630080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling
Description: Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
Study NCT06010888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib+mFOLFOX6/FOLFIRI
Description: Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard)
Study NCT06226636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: salt
Description: After ≥8 hr overnight fasting, participants will be required to ingest 780 mg of sodium (2 g salt) and BP measured every 10 minutes for 2 hours to determine IPROS. For SSBP, Participants are put on low salt (50 mmol Na/day) followed by seven days of high salt diet (250 mmol Na/day). Participants' mean arterial pressure (MAP) difference between low- and high-salt diet will be used to define salt sensitivity (MAP≥8 mmHg) and salt resistance (MAP≤5 mmHg).
Study NCT04941924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraductal Radio-Frequency Ablation
Description: The electrode employed in this study is the STARmed ELRA™ (Endo Luminal Radiofrequency Ablation) electrode; this is a CE marked device. The selected electrode will be connected to the VIVA™ Combo generator (also a CE marked device) and advanced over the guide wire.~The power of the generator should be set at either 7 or 10 W depending on the electrode used per manufacturer instructions. An ablation should then be applied at a temperature of 70 to 80℃ for 2 minutes. For longer length strictures or stent occlusions, the RFA probe is withdrawn from proximal to distal in a step by step fashion in respect to the access method used.
Study NCT04941924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary Stent Placement
Description: Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
Study NCT04941924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary Stent Placement
Description: Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
Study NCT06281431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echogenic nerve block needle
Description: A 22G 8-cm echogenic nerve block needle (LEAPMED, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The spread of the medication will be assessed through short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the incidence of punctures, and any associated complications are all meticulously appraised.
Study NCT06281431 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-echogenic nerve block needle
Description: A 22G 8-cm thin wall low bottom nerve block needle (KDL, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The distribution of the medication will be assessed using short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the number of punctures, and any associated complications are all meticulously appraised.
Study NCT01979796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ecig 24 mg nicotine
Description: Cigalike
Study NCT01979796 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ecig 0 mg nicotine
Description: Cigalike
Study NCT01979796 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine free inhalator
Description: Plastic CIG a Like
Study NCT04895943 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
Description: bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
Study NCT06755684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib combined Bevacizumab
Description: Befotertinib combined Bevacizumab
Study NCT06755684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib combined platinum-based double chemotherapy
Description: Befotertinib combined platinum-based double chemotherapy
Study NCT06751589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: 2.5 mg administered using a pre-filled injector once weekly for 4 weeks and then increase to 5 mg once weekly.
Study NCT06760468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the control group. Participants in the control group will undergo an 8-week placebo supplementation intervention. The placebo has a similar appearance and taste to the probiotic powder but does not contain active probiotic ingredients. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the placebo once a day at the same time to ensure the consistency and standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise capacity tests and blood sample collections will be conducted again. Comparing exercise performance and biochemical markers before and after t
Study NCT06760468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Experimental:~Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the experimental group. Participants in the experimental group will undergo an 8-week probiotic powder supplementation intervention. The dosage of the probiotic powder is set at 1x10\^9 CFU/kg·bw·d, which means ingesting 10 billion CFU (Colony-Forming Units) of probiotics per kilogram of body weight per day. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the probiotic powder once a day at the same time to ensure the consistency of the dosage and the standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise ca
Study NCT06759636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim N01
Description: 3.0 µg/kg, subcutaneous injection, once a week. Afterwards, refer to the platelet count evaluated during the visit before the next dosing cycle: ① If the platelet count is less than 50×10\^9/L, increase by 1-2μg/kg once a week; ② If the platelet count is between 50-99×10\^9/L, increase by 1μg/kg once a week. According to platelet count and symptoms, investigators can adjust the dosage to the maximum dosage of 10μg/kg once a week.
Study NCT06759636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Interleukin-11 (rhIL-11)
Description: 25-50μg/kg, subcutaneous injection, once a day
Study NCT06758596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: A capsule that contains only dextrose filler administered during the first or second laboratory visit.
Study NCT06758596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
Study NCT06758856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trimethylglycine
Description: Betaine anhydrous from sugar beets
Study NCT06758856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: 3 whole eggs
Study NCT06758856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Cellulose
Study NCT06760455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPR-30221616 Injection
Description: BPR-30221616 will be administered by subcutaneous (SC) injection
Study NCT06760455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Injection
Description: Sodium Chloride Injection will be administered by SC injection
Study NCT06759337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball Group
Description: Participants are given a colored silicone stress ball (5-7 cm diameter) 5 minutes before the procedure. During the procedure, they are instructed to squeeze the ball twice after counting to 10 and repeat this until the procedure is complete.
Study NCT06759337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-Holding Group
Description: The researcher holds one of the participant's hands during catheter insertion and removal. The researcher's fingers are closed but not interlocked and placed gently on the participant's hand without additional movements or gloves.
Study NCT06759909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin (DAPA)
Description: We will record all baseline characteristics (Age, sex, BMI, HR and BP), AF type, EHRA class, previous use of ADD (B blockers, Class I, III AAD), previous CV, prior cerebrovascular stroke and Co-morbidities (HTN, DM, IHD, HF, Renal impairment, peripheral arterial disease, OSAS). CHADS2Vasc score and HAS-BLEED score will be calculated. Trans-thoracic echocardiograms will be performed within 4 weeks before the rhythm control attempts to determine LA diameter and volumes and left ventricular hypertrophy and functions (EF and E/'e).~After enrollment, the patients will be treated with dapagliflozin (10 mg/d) or placebo at the time of rhythm control strategy and will continue daily treatment at the same dose till the 9 month follow-up period.
Study NCT06759415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise therapy was applied to individuals in both groups.
Study NCT06758752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ZAX.1400.EC.02
Description: ZAX.1400.EC.02, applied twice daily for 3 weeks after enrolment
Study NCT06758752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, applied twice daily for 3 weeks after enrolment
Study NCT06760442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcrestal implant placement
Description: Delayed implant placement 2 mm subcrestally in missing mandibular posterior site.
Study NCT06760442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crestal implant placement
Description: Delayed implant placement equicrestally in missing mandibular posterior site.
Study NCT06759064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid plus Sintilimab intraperitoneal injection
Description: At D-5\~D-1, drain the ascites by placing a tube in the abdominal cavity first, try to drain the ascites as much as possible according to the clinical routine, and record the amount of drainage.D1, D8, D15, D22 start the first immunocheckpoint inhibitor combined with zoledronic acid treatment, try to drain the ascites first, calculate the amount of drugs according to the patient's body weight, and then dissolve the corresponding dosage of immunocheckpoint inhibitor and zoledronic acid in 100 ml of saline and inject them into the abdominal cavity respectively, and then inject another 100 ml of saline according to the patient's tolerance. The corresponding dose of immune checkpoint inhibitor and zoledronic acid was dissolved in 100 ml of saline and injected into the abdominal cavity.
Study NCT06759571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser treatment
Description: to evaluate the effect of low-level laser therapy (LLLT) bone healing when used prior and following enucleation of intra-body maxillary cystic lesions
Study NCT05987969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alena mobile application
Description: This mobile application primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.
Study NCT04567888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Happify Teens
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study NCT05315180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-421286
Description: Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation
Study NCT06283784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yovis Capsules
Description: Subjects will assume the active treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
Study NCT06283784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will assume the placebo treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
Study NCT05463874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion Program
Description: The intervention consists of 8 sessions, one per week for 8 weeks, that last 1 hour and 30 minutes each. These sessions will cover a variety of mindfulness and self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice.
Study NCT05607940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood volume loss based blood transfusion
Description: Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.
Study NCT05607940 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemoglobin concentration based blood transfusion
Description: Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
Study NCT06200987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penile vibrator
Description: In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
Study NCT06521957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy
Study NCT06286436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: The intervention will consist of three different tasks that participants have to carry out while performing mental calculations (counting backwards from 100 by ones, twos, and threes). The three tasks will be as follows: grouping blocks of different colours into groups according to colour; picking up beans with a spoon and carrying them to a specific place; opening and closing a bottle cap with the affected hand. The total duration of the intervention will be 12 sessions, divided into three days per week for four weeks.
Study NCT06084936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1
Study NCT06084936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive IV glofitamab beginning Cycle 1 Day 8 for 12 cycles (cycle length = 21 days).
Study NCT06084936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Participants will receive IV rituximab every 28 days for up to 6 cycles (when in combination with bendamustine), or until disease progression (when in combination with lenalidomide).
Study NCT06084936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Participants will receive IV bendamustine on Days 1 and 2 Q4W for 6 cycles (cycle length = 28 days).
Study NCT06084936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide once daily on Days 1-21 Q4W until disease progression.
Study NCT06084936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
Study NCT06084936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
Study NCT05810285 — intervention group
Intervention type: DEVICE
Intervention: GKS Prime Flex Mobile knee
Description: Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis
Study NCT05227586 — intervention group
Intervention type: PROCEDURE
Intervention: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
Study NCT05227586 — intervention group
Intervention type: PROCEDURE
Intervention: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
Study NCT05132725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet therapy
Description: Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
Study NCT05755087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05755087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05755087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan